EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Robustness of CSF Aβ42/40 and Aβ42/P‐tau181 measured using fully automated immunoassays to detect AD‐related outcomes

Antoine Leuzy, Niklas Mattsson-Carlgren, Nicholas C Cullen, Erik Stomrud, Sebastian Palmqvist, Renaud La Joie, Leonardo Iaccarino, Henrik Zetterberg, Gil Rabinovici, Kaj Blennow, Shorena Janelidze, Oskar Hansson

Alzheimer's & Dementia · 2023-07 · 19 (7) · 2994-3004

DOI: 10.1002/alz.12897 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 21.01.2023. Verfasst von Antoine Leuzy und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Vetenskapsrådet, Hjärnfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This study investigated the comparability of cerebrospinal fluid (CSF) cutoffs for Elecsys immunoassays for amyloid beta (Aβ)42/Aβ40 or Aβ42/phosphorylated tau (p‐tau)181 and the effects of measurement variability when predicting Alzheimer's disease (AD)‐related outcomes (i.e., Aβ‐positron emission tomography [PET] visual read and AD neuropathology).

Methods

We studied 750 participants (BioFINDER study, Alzheimer's Disease Neuroimaging Initiative [ADNI], and University of California San Francisco [UCSF]). Youden's index was used to identify cutoffs and to calculate accuracy (Aβ‐PET visual read as outcome). Using longitudinal variability in Aβ‐negative controls, we identified a gray zone around cut‐points where the risk of an inconsistent predicted outcome was >5%.

Results

For Aβ42/Aβ40, cutoffs across cohorts were

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseHumansAmyloid beta-PeptidesBiomarkersPeptide Fragmentstau ProteinsImmunoassayPositron-Emission Tomography

Stichwörter der Autor:innen

Alzheimer's diseaseElecsysamyloid beta 42/amyloid beta 40amyloid beta 42/phosphorylated tau 181amyloid beta positron emission tomographycerebrospinal fluidplasma

Substanzen

amyloid beta-protein (1-42)Amyloid beta-PeptidesBiomarkersPeptide Fragmentstau Proteins

Autor:innen und Institutionen

  • Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden.
  • Department of Neurology, Skåne University Hospital, Lund, Sweden.
  • Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden.
  • Memory Clinic, Skåne University Hospital, Malmö, Sweden.
  • Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA.
  • Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.

Förderung

  • Vetenskapsrådet
  • Hjärnfonden

Zitieren

APA

Leuzy, A., Mattsson-Carlgren, N., Cullen, N. C., Stomrud, E., Palmqvist, S., La Joie, R., Iaccarino, L., Zetterberg, H., Rabinovici, G., Blennow, K., Janelidze, S., & Hansson, O. (2023). Robustness of CSF Aβ42/40 and Aβ42/P‐tau181 measured using fully automated immunoassays to detect AD‐related outcomes. Alzheimer's & Dementia, 19(7), 2994-3004. https://doi.org/10.1002/alz.12897

Vancouver

Leuzy A, Mattsson-Carlgren N, Cullen NC, Stomrud E, Palmqvist S, La Joie R, et al. Robustness of CSF Aβ42/40 and Aβ42/P‐tau181 measured using fully automated immunoassays to detect AD‐related outcomes. Alzheimer's & Dementia. 2023;19(7):2994-3004. doi:10.1002/alz.12897

BibTeX
@article{Leuzy2023,
  author = {Leuzy, Antoine and Mattsson-Carlgren, Niklas and Cullen, Nicholas C and Stomrud, Erik and Palmqvist, Sebastian and La Joie, Renaud and Iaccarino, Leonardo and Zetterberg, Henrik and Rabinovici, Gil and Blennow, Kaj and Janelidze, Shorena and Hansson, Oskar},
  title = {Robustness of CSF Aβ42/40 and Aβ42/P‐tau181 measured using fully automated immunoassays to detect AD‐related outcomes},
  journal = {Alzheimer's & Dementia},
  year = {2023},
  volume = {19},
  number = {7},
  pages = {2994--3004},
  doi = {10.1002/alz.12897}
}
Kostenlos starten →